Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Phone224-667-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.58 billion
Profitability
Miscellaneous
Employees103,000
Next Earnings DateN/A
OptionableOptionable
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories declared a quarterly dividend on Thursday, September 12th. Shareholders of record on Tuesday, October 15th will be paid a dividend of $0.32 per share on Friday, November 15th. This represents a $1.28 annualized dividend and a yield of 1.57%. The ex-dividend date is Friday, October 11th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) announced its earnings results on Wednesday, October, 16th. The healthcare product maker reported $0.84 earnings per share for the quarter, hitting analysts' consensus estimates of $0.84. The healthcare product maker had revenue of $8.08 billion for the quarter, compared to the consensus estimate of $8.10 billion. Abbott Laboratories had a return on equity of 17.26% and a net margin of 9.36%. The business's revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.75 earnings per share. View Abbott Laboratories' Earnings History.
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories issued an update on its FY19 earnings guidance on Wednesday, October, 16th. The company provided EPS guidance of $3.23-3.25 for the period, compared to the Thomson Reuters consensus estimate of $3.24.
What price target have analysts set for ABT?
17 analysts have issued 1-year price targets for Abbott Laboratories' stock. Their forecasts range from $68.00 to $98.00. On average, they anticipate Abbott Laboratories' share price to reach $86.08 in the next twelve months. This suggests a possible upside of 5.3% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.
What is the consensus analysts' recommendation for Abbott Laboratories?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.
Has Abbott Laboratories been receiving favorable news coverage?
Press coverage about ABT stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Abbott Laboratories earned a news impact score of -3.2 on InfoTrie's scale. They also assigned news coverage about the healthcare product maker a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Abbott Laboratories.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).
What other stocks do shareholders of Abbott Laboratories own?
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
- Mr. Robert B. Ford, Pres & COO (Age 45)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)
Who are Abbott Laboratories' major shareholders?
Abbott Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include CIBC Private Wealth Group LLC (0.13%), Gateway Investment Advisers LLC (0.05%), Hexavest Inc. (0.05%), Welch & Forbes LLC (0.04%), Gofen & Glossberg LLC IL (0.03%) and Artemis Investment Management LLP (0.03%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Which major investors are selling Abbott Laboratories stock?
ABT stock was sold by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, DNB Asset Management AS, Rhenman & Partners Asset Management AB, Hexavest Inc., CIBC Private Wealth Group LLC, Northpointe Capital LLC, Atalanta Sosnoff Capital LLC and Bremer Bank National Association. Company insiders that have sold Abbott Laboratories company stock in the last year include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Which major investors are buying Abbott Laboratories stock?
ABT stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State of Alaska Department of Revenue, Varma Mutual Pension Insurance Co, Dalton Greiner Hartman Maher & Co., Artemis Investment Management LLP, Hendley & Co. Inc., Harwood Advisory Group LLC and Pacer Advisors Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $81.78.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $144.54 billion and generates $30.58 billion in revenue each year. The healthcare product maker earns $2.37 billion in net income (profit) each year or $2.88 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.
What is Abbott Laboratories' official website?
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
